# Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients

> **NCT00284934** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 94 (actual)

## Conditions studied

- Kidney Diseases

## Interventions

- **DRUG:** Enteric-coated mycophenolate sodium (EC-MPS)
- **DRUG:** Tacrolimus
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT00284934
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2011-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00284934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00284934, "Enteric-coated Mycophenolate Sodium (EC-MPS) With Reduced-dose Tacrolimus Versus EC-MPS With Standard-dose Tacrolimus in Stable Kidney Transplant Recipients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00284934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*